2023
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Garvey W, Frias J, Jastreboff A, le Roux C, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad N, Bunck M, Benabbad I, Zhang X, investigators S, Abalos F, Manghi F, Zaidman C, Vico M, Aizenberg D, Costanzo P, Serra L, MacKinnon I, Hissa M, Vidotti M, Saraiva J, Alves B, Franco D, Moratto O, Murthy S, Goyal G, Yamasaki Y, Sato N, Inoue S, Asakura T, Shestakova M, Khaykina E, Troshina E, Vorokhobina N, Ametov A, Tu S, Yang C, Lee I, Huang C, Ou H, Freeman G, Machineni S, Klein K, Sultan S, Parsa A, Otero-Martinez J, Gonzalez A, Bhargava A, Brian S, Ince C, Plantholt S, Cole J, Lacour A, Vega D, de Souza J, Rohlf J, St. John R, Horowitz B, Audish H, Galindo R, Umpiperrez G, Ard J, Curtis B, Garvey W, Fraser N, Mandry J, Mohseni R, Mayfield R, Powell T, Vance C, Ong S, Lewy-Alterbaum A, Murray A, Al-Karadsheh A, Yacoub T, Roberts K, Fried D, Rosenstock J, Pulla B, Bode B, Frias J, Klaff L, Brazg R, Van J, Tan A, Briskin T, Rhee M, Chaicha-Brom T, Hartley P, Nunez L, Cortes-Maisonet G, Soucie G, Hsia S, Jones T. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet 2023, 402: 613-626. PMID: 37385275, DOI: 10.1016/s0140-6736(23)01200-x.Peer-Reviewed Original ResearchConceptsType 2 diabetesBody mass indexTreatment discontinuationAdverse eventsBodyweight reductionWeight managementGlucagon-like peptide-1 receptor agonistsInteractive web response systemPeptide-1 receptor agonistsGlucose-dependent insulinotropic polypeptideComputer-generated random sequenceFrequent adverse eventsPlacebo-controlled trialSerious adverse eventsIncretin-based therapiesPhase 3 trialWeb response systemTreatment of obesityWeekly tirzepatideCoprimary endpointsRescue therapySafety endpointWeek 72Safety profileStudy treatment
2022
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal Of Medicine 2022, 387: 205-216. PMID: 35658024, DOI: 10.1056/nejmoa2206038.Peer-Reviewed Original ResearchConceptsBody weightTreatment discontinuationAdverse eventsGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGlucose-dependent insulinotropic polypeptidePercentage changeDose escalation periodWeight-related complicationsCommon adverse eventsCoprimary end pointsBody mass indexSubstantial global morbidityTreatment of obesityMean percentage changePercentage of participantsMean body weightWeight reductionCardiometabolic measuresTreat populationPlacebo groupWeek 72Mean BMIWeekly dosesDose escalation